Phage Therapy Deal Benchmarks in Infectious Disease

Median Upfront

$513M

Range: $299M - $711M

Total Deal Value

$2.0B

Range: $1.3B - $2.6B

Royalty Rate

7.7% - 15.5%

Tiered up to 19.5%

Dev Milestones

$319M

Range: $228M - $414M

Model Your Deal

Market Analysis

Phage Therapy therapies in infectious disease have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 phage therapy asset in infectious disease is $513M, with total deal values reaching $2.0B. Development milestones average $319M, while regulatory milestones contribute $334M.

The infectious disease phage therapy landscape is characterized by variable competitive intensity across pathogen types, with high activity in antiviral and AMR spaces. MRNA platforms, novel antibiotics addressing resistance, and pandemic preparedness assets sustain strong licensee demand. The recommended deal structure allocates approximately 26% to upfront payments and 74% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for phage therapy infectious disease deals range from 7.7% to 15.5% at the base tier, with tiered escalation reaching 11.7%-19.5% on blockbuster sales. Commercial milestones averaging $799M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a phage therapy infectious disease licensing deal?

Based on our analysis, Phase 2 phage therapy licensing deals in infectious disease average $513M in upfront payments, with a range of $299M to $711M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for phage therapy infectious disease transactions?

The median total deal value for Phase 2 phage therapy assets in infectious disease is $2.0B, ranging from $1.3B to $2.6B. This includes development milestones ($319M), regulatory milestones ($334M), and commercial milestones ($799M).

What royalty rates are standard for phage therapy deals in infectious disease?

Base royalty rates for phage therapy infectious disease transactions range from 7.7% to 15.5%, with tiered escalations reaching 11.7%-19.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in phage therapy infectious disease deals?

Phage Therapy infectious disease deals allocate approximately 74% of total deal value to milestones. Development milestones ($319M) make up the largest share, followed by commercial milestones ($799M) and regulatory milestones ($334M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Infectious Disease

View

Monoclonal Antibody in Infectious Disease

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating